Yankees Score with ...
Health Care: Drugs
Alkermes PLC (ALKS: NASDAQ)
$32.84 -0.16 | -0.48%
05/24/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 33.00 |
| 52 Week High | 33.17 |
| 52 Week Low | 14.82 |
| Avg. Daily Vol. (Mil) | 1.35 |
| Beta (3 year) | 1.21 |
| Share Related Items | |
| Mkt Cap (Mil) | 4,394.51 |
| Shares Out (Mil) | 133.17 |
| Float (Mil) | 80.30 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 4.30 |
| Current Ratio | 5.00 |
| LT Debt/ Equity | 0.39 |
| Total Debt / Equity | 0.40 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 8.10 |
| Price/Book | 4.78 |
| Price/Cash Flow | 54.60 |
| Per Share Data | |
| Earnings | -0.37 |
| Sales | 4.07 |
| Book Value | 6.91 |
| Cash Flow | 0.60 |
| Business Summary | |
|---|---|
| Alkermes PLC is a biotechnology company committed to developing innovative medicines to improve patients' lives. | |
| General Information | |
| Connaught House
1 Burlington Road Dublin, 4 |
|
| www.alkermes.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 1200 | |
| CEO: Richard F. Pops | |
| Short Interest | |
| Current Month (Mil) | 5.20 |
| Previous Month (Mil) | 5.32 |
| Short Interest Ratio (Days) | 3.00 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -2.90 |
| Return on Investments | -3.20 |
| Profitability | |
| Gross Margin | 74.10 |
| EBIT Margin | 1.40 |
| Profit Margin | -7.60 |
Portfolios with ALKS
- Portfolio NameUser Type
- ContributorTechnical Setups for the We...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks With Big Insider Buy...
- UserInvestments
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- Usergterryburns
- Usermitetwo Portfolio 1
Latest ALKS Headlines from TheStreet
- ALKS July Options Begin Trading 05.20.13 | 02:05 pm
- Alkermes Stock Hits New 52-Week High (ALKS) 05.20.13 | 10:05 am
- SALT 2013: The 5 Best Ideas of the Year Ahead 05.10.13 | 04:05 pm
- Alkermes Stock Hits New 52-Week High (ALKS) 04.19.13 | 02:04 pm
- Cramer's 6 Stocks in 60 Seconds: LDK ALKS APA BBY UNP HFC (Update 1) 04.18.13 | 05:04 pm
- 3 Stocks Advancing The Health Care Sector 04.17.13 | 01:04 pm
- Three Cheers For Alkermes Running A Depression Study In The US of A 04.17.13 | 10:04 am
- Alkermes Stock Gaps Up On Today's Open (ALKS) 04.17.13 | 10:04 am
- Cramer's 6 Stocks in 60 Seconds: EA BTU ALKS SLB PEP SWN (Update 1) 03.26.13 | 05:03 pm
- Alkermes: A Biotech With Multiple Drivers
02.28.13 | 11:02 am
Press Releases for ALKS
- Alkermes’ Corporate Presentation To Be Webcast At Three Upcoming Conferences - Business Wire 02.19.13 | 04:02 pm
- Alkermes’ Corporate Presentation To Be Webcast At Two Upcoming Conferences - Business Wire 02.05.13 | 04:02 pm
- Alkermes Plc Reports Third Quarter Fiscal 2013 Financial Results - Business Wire 01.31.13 | 07:01 am
- Alkermes To Host Conference Call To Discuss Financial Results For Third Quarter Of Fiscal 2013 - Business Wire 01.24.13 | 04:01 pm
- Alkermes Announces Notice Of Allowance Of Key U.S. Patent For Aripiprazole Lauroxil, A New Schizophrenia Drug Candidate - Business Wire 01.03.13 | 07:01 am
- Alkermes Expands CNS Pipeline And Announces Positive Results From Phase 1 Study Of ALKS 3831, A Novel Antipsychotic Therapy For The Treatment Of Schizophrenia - Business Wire 01.03.13 | 07:01 am
- Alkermes’ Corporate Presentation To Be Webcast At The 31st Annual J.P. Morgan Healthcare Conference - Business Wire 01.02.13 | 04:01 pm
- Alkermes And Collaborators To Present Data From Three Ongoing Clinical Development Programs At Two Major Medical Meetings - Business Wire 12.03.12 | 07:12 am
- Alkermes’ Corporate Presentation To Be Webcast At Two Upcoming Conferences - Business Wire 11.07.12 | 04:11 pm
- Alkermes Plc Reports Second Quarter Fiscal 2013 Financial Results - Business Wire 11.01.12 | 07:11 am
Partner Headlines for ALKS
- Alkermes Leaps On Study Results, May Offer New Entry - Investor's Business Daily 04.17.13 | 05:04 pm
- Indexes Notch Sharp Declines; New 52-Week Low For Apple - Investor's Business Daily 04.17.13 | 04:04 pm
- Stocks Hold Near Lows, But Alkermes Soars To New High - Investor's Business Daily 04.17.13 | 03:04 pm
- Biotech Alkermes Poised To Swell On Pipeline Wins - Investor's Business Daily 04.16.13 | 05:04 pm
- Pockets of Strength In Top Groups, Few Leaders Basing - Investor's Business Daily 04.15.13 | 06:04 pm
- Alkermes Aims At Bipolar, Addiction Markets To Grow - Investor's Business Daily 04.15.13 | 04:04 pm
- Biotech Watch-List: Medicine Co., Alkermes, Celgene - Investor's Business Daily 03.11.13 | 05:03 pm
- Foreign Stocks Also Fall In A Correction - Investor's Business Daily 02.26.13 | 05:02 pm
- Alkermes Finding Support At 10-Week Average - Investor's Business Daily 02.21.13 | 05:02 pm
- Stocks Hold Near Session Lows; Generac Stumbles - Investor's Business Daily 02.21.13 | 03:02 pm
